Sugi Predict

Sugi Predict / Compounds / SCHEMBL5881952

SCHEMBL5881952

SCHEMBL5881952

Cc1[nH]c2ccc(C(=O)O)cc2c1Cc1ccc2ccccc2c1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN5 P54829 1/20 0.53
▸ KDM4E B2RXH2 6/20 0.48
▸ ALDH1A1 P00352 5/20 0.48
▸ THRB P10828 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ PPARG P37231 1/20 0.47
▸ PSMD14 O00487 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ POLB P06746 2/20 0.43
▸ F2 P00734 2/20 0.43
▸ F10 P00742 2/20 0.43
▸ PLG P00747 2/20 0.43
▸ PLAU P00749 2/20 0.43
▸ PRSS1 P07477 2/20 0.43
▸ MAPT P10636 6/20 0.41
▸ GAA P10253 3/20 0.41
▸ CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882307 0.89 GPR84 (0.50) PTPN5KDM4EALDH1A1HPGDPOLB
SCHEMBL5881972 0.85 HDAC3 (0.46) PTPN5POLBMAPTTP53MMP3
SCHEMBL5882574 0.82 PTPN5 (0.50) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5882123 0.81 HDAC3 (0.47) MAPTGAATP53
SCHEMBL5882270 0.80 PPARG (0.39) PTPN5KDM4EALDH1A1PPARGMAPT
SCHEMBL6320284 0.79 MAPT (0.40) PTPN5POLBMAPTLMNAMEN1
SCHEMBL5881790 0.78 PTPN5 (0.58) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6301167 0.78 KDM4E (0.38) KDM4EALDH1A1HPGDPPARGTDP1
SCHEMBL5884525 0.78 HDAC3 (0.43) PTPN5KDM4EALDH1A1POLBMAPT
SCHEMBL6321446 0.78 MAPT (0.40) ALDH1A1PPARGRECQLPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 — — US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 — — US disclosed
CN-1150167-C Indole derivatives ����ҩƷ��ҵ��ʽ���� 2004-05-19 — — CN disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 — — US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 — — US disclosed
CN-1303371-A Indole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-11 — — CN disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PTPN5 2703/4885KDM4E 2944/4885ALDH1A1 1463/4885
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A PTPN5 108/4885KDM4E 942/4885ALDH1A1 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.